TY - JOUR T1 - SCLERODERMA AND MALIGNANCY JF - medRxiv DO - 10.1101/2021.01.25.21250479 SP - 2021.01.25.21250479 AU - Jaime A. Vondenberg AU - David R. Cisneros AU - Adnan N. Kiani AU - Maheswari Muruganandam AU - Sharon E. Nunez AU - N. Suzanne Emil AU - Wilmer L. Sibbitt, Jr. Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/27/2021.01.25.21250479.abstract N2 - Background/Objectives Describe clinical characteristics of malignancy-associated scleroderma in a regional population.Methods Scleroderma patients with current or past malignancy were prospectively identified from a cohort of 125 scleroderma subjects of a largely Hispanic population. Demographic information included scleroderma subtype, serologies, cancer diagnosis, age at diagnosis, co-morbid conditions, therapies, and survival outcomes.Results 16.0% (20/125) of scleroderma patients were identified as having a malignancy. The mean age of malignancy onset and scleroderma onset were 55.6±10.3 and 52.7±12.9 years respectively (95% CI of difference: -4.6 <2.9< 10.4, p=0.44). Antinuclear antibody was positive in 70%, anticentromere antibody in 35.0%, and anti-topoisomerase antibodies in 25%. Tumor proportions were adenocarcinomas 55.0% (11/20) (1 gastric, 2 pancreatic, 1 lung, 2 thyroid, 5 breast), 15% (3/20) squamous cell carcinoma (1 skin, 1 uterine cervical, and 1 rectal), and 20% (4/20) benign tumors (2 meningiomas, 1 renal adenoma, 1 plasma cell). Age of onset of scleroderma greater than 42 years respectively accounted for 85% of all cancer cases. The standardized incidence ratio (SIR) was 2.0 (CI at 95%: 1.2<2<3.1), indicating 100% increase in cancer risk. Treatment of the malignancy did not resolve the scleroderma in any of the cases. Five-year survival after cancer diagnosis was 70.0%, although 2 of the survivors had tumor recurrence.Conclusions Malignancy, especially adenocarcinoma, occurs frequently in scleroderma in minority populations with up to 16% of patients affected. High-risk patients are those with scleroderma-onset greater than 42 years in whom routine screening for common cancers should be undertaken.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNOT A CLINICAL TRIALFunding StatementThere was no funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board (IRB) the Human Research Review Committee (HRRC) of the University of New Mexico Health Sciences Center and all subjects provided informed written consent before all procedures and examinations. The study adhered to the principles in the Declaration of Helenski.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeindentified data are available as requested as permitted by the local IRB - the Human Research Review Committee (HRRC) of the University of New Mexico Health Sciences Center. ER -